Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that CEO and President Michael Feldschuh will present a corporate overview at the H.C. Wainwright BioConnect 2022 Virtual Conference, which is taking place on January 10 – 13, 2022.

Mr. Feldshuh will provide company updates and key highlights, including a new patent award and progress with BVA-100® next generation development.  The presentation will be available on-demand beginning at 7:00 a.m. ET on Monday, January 10, 2022.

Register for the conference: https://hcwevents.com/bioconnect/

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all.